Shield Therapeutics plc (LON:STX – Get Free Report)’s share price rose 9.4% during trading on Tuesday . The company traded as high as GBX 3.07 ($0.04) and last traded at GBX 2.90 ($0.04). Approximately 909,442 shares traded hands during trading, a decline of 80% from the average daily volume of 4,498,458 shares. The stock had previously closed at GBX 2.65 ($0.03).
Shield Therapeutics Stock Up 9.4 %
The firm has a 50 day moving average price of GBX 3.83 and a 200-day moving average price of GBX 2.98. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50. The firm has a market cap of £22.68 million, a PE ratio of -65.00 and a beta of 1.42.
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
See Also
- Five stocks we like better than Shield Therapeutics
- What is the Shanghai Stock Exchange Composite Index?
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- When to Sell a Stock for Profit or Loss
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- Industrial Products Stocks Investing
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
